Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. is a publicly traded, commercial-stage biopharmaceutical company focused on developing precision genetic medicines for rare diseases, particularly neuromuscular disorders. Headquartered in Cambridge, Massachusetts, the company was founded in 1980, initially incorporated as AntiVirals, Inc., and later renamed AVI BioPharma before becoming Sarepta Therapeutics in 2012. As of December 31, 2025, Sarepta had 835 employees. The company's trailing 12-month revenue as of March 31, 2026, was reported at $2.18 billion, with a market capitalization of $1.76 billion as of May 26, 2026.

Sarepta specializes in RNA-targeted therapies, gene therapies, and other genetic therapeutic modalities. Its product portfolio includes FDA-approved treatments for Duchenne muscular dystrophy (DMD), such as EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS (the first gene therapy for DMD). The company also has a pipeline of over 40 investigational programs spanning gene therapy, RNA technologies, and gene editing for various neuromuscular and other rare diseases, including limb-girdle muscular dystrophies and Charcot-Marie-Tooth disease.

Sarepta Therapeutics exhibits an active patent litigation posture as a plaintiff, with its single tracked case appearing in the U.S. Patent and Trademark Office (PTAB). This indicates a focus on challenging the validity of competitor patents.

The tracked case, Sarepta Therapeutics, Inc. v. Genzyme Corp., involves inter partes review (IPR) proceedings at the PTAB. These IPRs challenge patents related to gene therapy products, including Sarepta's Elevidys. Some of these IPRs are connected to ongoing litigation between Sarepta and Genzyme in district court.